The Journal of Laryngology & Otology · 1995 · 27 citations · 26 references
MedicineAudiologyOncologyChemotherapyHearing AssessmentOtologyConcurrent ChemoradiationHearing ImpairmentHearing LossOtotoxicityRadiation TherapyRadiation ToxicityChemotherapy-induced OtotoxicityChemotherapy-related OtotoxicityCisplatin OtotoxicityCochlear ToxicityHearing Threshold LevelHearing Threshold MeasurementPlatinum-based OtotoxicityRadiation Therapy Combinations
WR 2721 (ethiofos) protects against the toxic effects of the heavy metal compound cisplatin, which is used in the treatment of solid tumours. In a Phase I protocol designed to determine the maximum dose of WR 2721 which could be tolerated when administered in combination with cisplatin and radiation therapy to patients with cervical carcinoma, 11 patients were evaluated by audiologic testing before and after cisplatin WR 2721 administration in an attempt to identify the degree of ototoxicity. Forty-five per cent were noted to have significant hearing threshold changes, predominantly in the high frequencies. There were no significant changes in the speech frequencies in this series. This contrasts with the greater degrees of ototoxicity observed in controls treated in the same way who received cisplatin without WR 2721 protection.
26
The role of WR-2721 in radiotherapy and/or chemotherapy.
John M. Yuhas, James Spellman, Filip Čulo · PubMed · 1980 · 282 citations
Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721
Joan E. Mollman, Donna Glover, W. Michael Hogan et al. · Cancer · 1988 · 215 citations
Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration.
Roger R. Reddel, Richard Kefford, Justin Grant et al. · PubMed · 1982 · 188 citations
Medicine, Audiology, Otolaryngology +16
Ototoxicity of low- and moderate-dose cisplatin
Steven D. Schaefer, Jimmy D. Post, Lanny Garth Close et al. · Cancer · 1985 · 181 citations · Full text
Medicine, Oncology, Otolaryngology +17